# Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women

> **NCT02046148** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 75 (actual)

## Conditions studied

- GBS Disease
- Streptococcus Agalactiae

## Interventions

- **BIOLOGICAL:** GBS trivalent vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02046148
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-18
- **Primary completion:** 2015-12-30
- **Final completion:** 2016-03-26
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2020-12-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02046148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02046148, "Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02046148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*